Lin Shen
Peking University Cancer Hospital & Institute · Peking University Cancer Hospital, Beijing, Beijing 100142, China · Heze Hospital of Traditional Chinese Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lin Shen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:11 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07720193 · A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECNanjing Leads Biolabs Co.,Ltd · not yet recruiting · Advanced Extrapulmonary Neuroendocrine Carcinoma · principal investigator
- Ph3NCT07700979 · Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaAkeso · recruiting · Gastric / Gastroesophageal Junction Adenocarcinoma · principal investigator
- Early Ph1NCT07673419 · A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung CancerBeijing Geekgene Technology Co., LTD · not yet recruiting · Advanced Lung Cancer · principal investigator
- Ph2NCT07669415 · A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid TumorsLaNova Medicines Limited · recruiting · Advanced Solid Tumor · principal investigator
- N/ANCT07547787 · A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)Akeso · recruiting · Locally Advanced Unresectable or Metastatic Gastric Cancer · principal investigator
- Ph1NCT07486700 · The Phase I Study of SIG001 Antibody on Cancer Therapy.Peking University · not yet recruiting · Neoplams · principal investigator
- Ph1NCT07482319 · A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid TumorsBeijing Geekgene Technology Co., LTD · not yet recruiting · Advanced Solid Tumors · principal investigator
- Ph1NCT07406984 · Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric JunctionBeijing Immunochina Medical Science & Technology Co., Ltd. · not yet recruiting · Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction · principal investigator
- Ph2NCT07390383 · A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]Nanjing Leads Biolabs Co.,Ltd · recruiting · Advanced Solid Tumour · principal investigator
- Ph3NCT07362186 · LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaLaNova Medicines Limited · recruiting · Locally Advanced or Metastatic GC and GCJ Adenocarcinoma · principal investigator
- Ph2NCT07331155 · A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd · recruiting · Advanced Solid Tumour · principal investigator
- Ph1/Ph2NCT07259590 · A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationGenfleet Therapeutics (Shanghai) Inc. · recruiting · Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer) · principal investigator
- Ph1NCT07208136 · A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid TumorsJemincare · recruiting · Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT07069062 · A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid TumorsSichuan Huiyu Pharmaceutical Co., Ltd · recruiting · Solid Tumor · study director
- Ph1NCT06718738 · Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal CancerBeijing Immunochina Medical Science & Technology Co., Ltd. · recruiting · Colorectal Cancer (CRC) · principal investigator
- Ph1/Ph2NCT06708663 · HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd. · recruiting · Biliary Tract Cancer, Melanoma · principal investigator
- Ph2NCT06580574 · Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersPeking University · recruiting · Gastric Cancer, Colon Cancer, MSI-H · principal investigator
- Ph1NCT06541639 · EVM16 Injection as a Single and Combination With Tislelizumab in Solid TumorsPeking University · recruiting · Advanced or Recurrent Solid Tumors · principal investigator
- Early Ph1NCT06380309 · A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFEPeking University · recruiting · Advanced Malignant Solid Tumor of Digestive System · principal investigator
- Ph1NCT06353152 · Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction AdenocarcinomaPeking University · unknown · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1NCT06349811 · A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid TumorsBiokin (Shanghai) Biopharmaceutical Co., Ltd. · recruiting · Locally Advanced or Metastatic Solid Tumors · principal investigator
- Ph3NCT06343116 · Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal CancerBiotech Pharmaceutical Co., Ltd. · withdrawn · Refractory Metastatic Colorectal Cancer · study chair
- Ph3NCT06341335 · A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaAkeso · recruiting · Gastric and Gastroesophageal Junction Adenocarcinoma · principal investigator
- N/ANCT06331923 · Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients With DiabetesBeijing Tsinghua Chang Gung Hospital · completed · Comprehensive Complication Index · principal investigator
- Ph3NCT06304974 · A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)Sichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph1NCT06256055 · Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid TumorsUTC Therapeutics Inc. · unknown · Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer · principal investigator
- Ph1NCT06240546 · First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.Luye Pharma Group Ltd. · recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT06239623 · ERK Inhibitor JSI-1187 in Advanced Solid TumorsJS InnoPharm, LLC · unknown · Solid Tumor, NSCLC, Melanoma · principal investigator
- Ph2NCT06222944 · Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJAPeking University · unknown · Gastric Cancer, Adenocarcinoma of Esophagogastric Junction · principal investigator
- Ph1NCT06197178 · A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)Peking University · terminated · Advanced Gastrointestinal Tumors · principal investigator
- Ph1NCT06196762 · Phase I of XKH002 Injection in PatientsZhejiang Kanova Biopharmaceutical Co., LTD · unknown · Advanced or Metastatic Solid Tumors · principal investigator
- Ph1NCT06170294 · MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid TumorsPeking University · recruiting · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT06157827 · A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaNanjing Leads Biolabs Co.,Ltd · recruiting · Advanced Neuroendocrine Carcinoma · principal investigator
- Ph1NCT06134960 · NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPeking University · recruiting · Gastric Cancer, Pancreatic Cancer, Solid Tumor · principal investigator
- Ph2NCT06099821 · KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadePeking University Cancer Hospital & Institute · active not recruiting · Digestive System Cancers · principal investigator
- Ph3NCT06086457 · PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · recruiting · Esophageal Neoplasms · principal investigator
- Ph1/Ph2NCT06008925 · Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerCNBG-Virogin Biotech (Shanghai) Ltd. · unknown · Metastatic Gastric Cancer · principal investigator
- Ph2NCT06008054 · A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Esophageal Cancer, Gastric Cancer, Colorectal Cancer · principal investigator
- Ph2NCT05985109 · KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerPeking University Cancer Hospital & Institute · terminated · Colorectal Cancer · principal investigator
- Ph1NCT05981235 · Phase 1 Trial of AZD6422 in CLDN18.2+ GI TumorsPeking University · completed · Gastrointestinal Tumors · principal investigator
- Ph1/Ph2NCT05964543 · The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal TumorsQureBio Ltd. · unknown · Gastroesophageal Junction (GEJ) Adenocarcinoma · principal investigator
- Ph1NCT05950815 · A Study of PM1015 in Patients With Advanced Solid TumorsBiotheus Inc. · unknown · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT05830097 · A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid TumorsCoherent Biopharma (Hefei) Co., Ltd. · unknown · Cancer, Breast, Cancer, Lung, Cancer of Pancreas · principal investigator
- Ph1NCT05751356 · TR128 in Patients With Advanced Solid TumorsTarapeutics Science Inc. · unknown · Advanced Solid Tumor · principal investigator
- Ph1NCT05730361 · Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid TumorsPeking University · unknown · Digestive System Malignant Solid Tumors · principal investigator
- N/ANCT05697107 · Ripretinib in Chinese Patients With Advanced GIST: a Real World StudyPeking University · unknown · Gastrointestinal Stromal Tumors · principal investigator
- N/ANCT05649163 · Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard TherapyShen Lin · unknown · HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma · principal investigator
- Early Ph1NCT05638828 · A Study of RD14-01 in Patients With Advanced Solid TumorsShen Lin · unknown · Solid Tumor · principal investigator
- Ph1/Ph2NCT05518045 · A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsLaNova Medicines Limited · active not recruiting · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT05508659 · A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph1NCT05393986 · Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid TumorsPeking University · unknown · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1/Ph2NCT05383482 · Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1Laekna Limited · completed · Solid Tumor, NSCLC, Cervical Cancer · principal investigator
- Early Ph1NCT05287165 · Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System NeoplasmsBeijing Immunochina Medical Science & Technology Co., Ltd. · unknown · Advanced Solid Tumors, Digestive System Neoplasms, Pancreatic Cancer Resectable · principal investigator
- Ph1/Ph2NCT05278728 · Phase IIa Study of Nimotuzumab to Treat Colorectal CancerBiotech Pharmaceutical Co., Ltd. · completed · Colorectal Cancer · principal investigator
- Ph1NCT05262491 · A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Gastrointestinal Tumor · principal investigator
- N/ANCT05227378 · Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric CancerShen Lin · unknown · Gastric Cancer · principal investigator
- Ph1/Ph2NCT05170958 · A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant TumorsNanjing Leads Biolabs Co.,Ltd · recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT05167071 · HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors StudyHarbour BioMed (Guangzhou) Co. Ltd. · active not recruiting · Solid Tumors, Neuroendocrine Tumors, CRC · principal investigator
- N/ANCT05165602 · Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring SystemPeking University · unknown · HER2 Positive Gastric Cancer · study director
- Ph1/Ph2NCT05154201 · Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.Orinove, Inc. · completed · Effect of Drug · principal investigator
- Ph1/Ph2NCT05139082 · Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System TumorsPeking University · unknown · Digestive System Tumors · study chair
- Ph2NCT05030246 · Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerPeking University · unknown · Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer · principal investigator
- Ph2NCT05022654 · SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Sichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Esophageal Squamous Cell Carcinomas · principal investigator
- Ph3NCT05015621 · A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaHutchison Medipharma Limited · unknown · Advanced Neuroendocrine Carcinoma · principal investigator
- Ph3NCT05008783 · A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ AdenocarcinomaAkeso · completed · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04988191 · Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal CancerPeking University · unknown · Colorectal Carcinoma · principal investigator
- Ph1/Ph2NCT04982276 · A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaAkeso · recruiting · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1NCT04973098 · Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular CarcinomaPeking University · unknown · Advanced Hepatocellular Carcinoma · principal investigator
- Ph2NCT04923932 · Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsHutchison Medipharma Limited · completed · Gastric Cancer, Esophagogastric Junction Disorder · principal investigator
- Ph1NCT04906473 · Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid TumorsKunming Pharmaceuticals, Inc. · unknown · Advanced Solid Tumor · principal investigator
- Ph2NCT04891198 · ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors3D Medicines (Sichuan) Co., Ltd. · recruiting · Solid Tumor · principal investigator
- Ph2NCT04880811 · Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationPeking University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph3NCT04848753 · Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaShanghai Junshi Bioscience Co., Ltd. · active not recruiting · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT04723030 · The Transformation of Locally Advanced Pancreatic Cancer.Peking University · unknown · Locally Advanced Pancreatic Cancer · principal investigator
- Ph1NCT04606472 · A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Solid Tumor · principal investigator
- N/ANCT04584008 · Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsPeking University · unknown · Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma · principal investigator
- Ph1/Ph2NCT04581473 · Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionCARsgen Therapeutics Co., Ltd. · active not recruiting · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT04521179 · Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsJiangsu Alphamab Biopharmaceuticals Co., Ltd · completed · HER2-positive Solid Tumors · principal investigator
- N/ANCT04500990 · MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational StudyPeking University · unknown · Immunotherapy, Digestive System Neoplasm · principal investigator
- Ph1NCT04280341 · JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid TumorsPeking University · unknown · HER2-Positive Solid Tumors · principal investigator
- Ph1/Ph2NCT04254939 · A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCStone Pharmaceuticals · completed · Gastrointestinal Stromal Tumors · principal investigator
- Ph3NCT04233151 · QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and SafetyQilu Pharmaceutical Co., Ltd. · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT04169672 · Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsHutchison Medipharma Limited · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT04130763 · Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1Peking University · completed · Gastrointestinal System Cancer · principal investigator
- Ph1NCT04040699 · KN026 Combined With KN046 in Subjects With HER2 Positive Solid TumorPeking University · completed · HER2 Positive Solid Tumor · principal investigator
- Ph2/Ph3NCT03992911 · Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaPeking University · unknown · Neuroendocrine Carcinoma of the Bladder · principal investigator
- Ph2NCT03940976 · Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Peking University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph1NCT03879057 · Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid TumorsPeking University · unknown · Solid Tumor · principal investigator
- Ph1NCT03874897 · Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.Peking University · completed · Advanced Solid Tumor · principal investigator
- Ph2NCT03736889 · Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsBeiGene · recruiting · MSI-H/dMMR Solid Tumors · principal investigator
- Ph1NCT03713905 · Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid TumorsGuangzhou Gloria Biosciences Co., Ltd. · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT03710265 · SHR-1701 in Metastatic or Locally Advanced Solid TumorsJiangsu HengRui Medicine Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph2NCT03667170 · KN035 for dMMR/MSI-H Advanced Solid Tumors3D Medicines (Sichuan) Co., Ltd. · active not recruiting · Solid Tumor · principal investigator
- Ph2NCT03636308 · Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic CancerPeking University · unknown · Pancreatic Cancer · principal investigator
- Ph2NCT03567629 · Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal CancerPeking University · unknown · mCRC · principal investigator
- Ph1NCT03480256 · Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric CancerPeking University · unknown · Gastric Cancer · principal investigator
- Ph2NCT03472365 · A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerJiangsu HengRui Medicine Co., Ltd. · completed · Gastric Cancer, GastroEsophageal Cancer · principal investigator
- Ph1NCT03312842 · A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCStone Pharmaceuticals · completed · Advanced Cancer · principal investigator
- Ph2NCT03185988 · Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemShen Lin · unknown · Targeted Therapy, HER2, Biliary Tract Cancer · principal investigator
- Ph1NCT03167853 · Study of JS001 in Patients With Advanced Neuroendocrine TumorsPeking University · completed · Neuroendocrine Tumors · principal investigator
- Ph2NCT03126708 · Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaPeking University · unknown · Esophageal Cancer, Squamous Cell, Cetuximab Effect, Chemotherapy Effect · principal investigator
- Ph1NCT02978482 · A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesAstraZeneca · completed · Advanced Malignancy · principal investigator
- Ph1NCT02940132 · A Study of SC10914 in Patients With Advanced Solid TumorsJiangxi Qingfeng Pharmaceutical Co. Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph1NCT02881190 · Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid TumorsRemeGen Co., Ltd. · completed · Solid Tumors · principal investigator
- Ph3NCT02611700 · Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaBiotech Pharmaceutical Co., Ltd. · unknown · Esophageal Squamous Cell Carcinomas · study chair
- Ph3NCT02390947 · Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)Jiangsu HengRui Medicine Co., Ltd. · completed · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent · principal investigator
- Ph1NCT02245204 · Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced CancersSichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd · completed · Advanced Cancer · study chair
- Ph1/Ph2NCT02233205 · Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive SystemPeking University Cancer Hospital & Institute · unknown · Gastrointestinal Neoplasms · principal investigator
- Ph2NCT02016274 · Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell CancerShen Lin · unknown · Esophageal Squamous Cell Cancer · principal investigator
- Ph2NCT02016287 · Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell CancerShen Lin · unknown · Esophageal Squamous Cell Cancer, Elderly Patients · principal investigator
- Ph1/Ph2NCT01993784 · Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.Peking University · unknown · Esophageal Squamous Cell Cancer · principal investigator
- Ph1NCT01985555 · Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsHutchison Medipharma Limited · completed · Tumors · principal investigator
- N/ANCT01860144 · An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal CancerPeking University · unknown · Metastatic Colorectal Cancer · principal investigator
- N/ANCT01847794 · HER2 Positive CTC in Advanced Gastric CancerPeking University · unknown · HER2 Positive Advanced Gastric Cancer · principal investigator
- N/ANCT01848015 · Circulating Tumor Cells (CTCs) in Advanced Gastric CancerPeking University · unknown · Gastric Cancer · principal investigator
- Ph2NCT01811277 · SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic CancerPeking University · unknown · Biliary Tract Cancer, Periampullary Adenocarcinoma, Pancreatic Cancer · principal investigator
- N/ANCT01549067 · The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation SurveyChinese Medical Doctor Association · unknown · Advanced Malignant Neoplasm, Colorectal Cancer · principal investigator
- Ph2NCT01180153 · Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)Peking University Cancer Hospital & Institute · unknown · Biliary Tract Cancer · principal investigator
- Ph3NCT01015339 · Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionPeking University · unknown · Advanced Gastric Cancer · principal investigator
- Ph2NCT00842491 · Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric CancerPeking University · completed · Advanced Gastric Cancer · principal investigator
- Ph3NCT00630045 · Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver MetastasisPeking University People's Hospital · unknown · Colorectal Cancer, Resectable Liver Metastasis · principal investigator
- Ph2NCT00477711 · A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric CancerPeking University · completed · Gastric Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:11 UTC. The ranking covers the 200 most relevant of 584 PubMed records, and a shared surname and initials can bring in a namesake. All 584 on PubMed
- 5,948 citationsRCR 150.9
- 2,656 citationsRCR 153.2
- 2,611 citationsRCR 66.1
- 1,422 citationsRCR 77.3
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.N Engl J Med · 20211,043 citationsRCR 57.7
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.J Clin Oncol · 2020933 citationsRCR 38.9
- 627 citationsRCR 54.7
- 618 citationsRCR 32.2
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.Nat Med · 2022547 citationsRCR 35.5
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.N Engl J Med · 2021533 citationsRCR 26.7